



09/01/05

76429
AF

Express Mail No.: EV 475 141 303 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Srivastava

Confirmation No.: 1802

Application No.: 09/873,403

Group Art Unit: 1642

Filed: June 4, 2001

Examiner: Christopher H. Yaen

For: COMPLEXES OF ALPHA(2)-
MACROGLOBULIN AND ANTIGENIC
MOLECULES FOR IMMUNOTHERAPY

Attorney Docket No.: 8449-178-999
(CAM #708584-999177)

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND § 1.97(d)**

MAIL STOP: AF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicant respectfully direct the Examiner's attention to the reference **EM** listed on the attached List of References Cited by Applicant. A copy of this reference is attached hereto as **Exhibit 1**.

Applicant respectfully requests that the Examiner review the listed reference and that this reference be made of record in the file history of the application. Identification of the listed reference is not meant to be construed as an admission of Applicant or Attorneys for Applicant that such reference is available as "prior art" against the subject application.


09/06/2005 MAHME1 00000058 503013 09873403
01 FC:1806 180.00 DA

The reference listed on the attached List of References Cited by Applicant was cited in a European Search dated May 30, 2005, which was issued in connection with European Patent Application No. 01944267.2, which is related to the subject application. The EPO search also identified the following four references: WO 94/14976, published July 7, 1994; WO 96/10411, published April 11, 1996; Chu et al., 1994, "Adjuvant-free in vivo targeting. Antigen delivery by α_2 -macroglobulin enhances antibody formation," *J. Immunology* 152(4):1538-1545; and Binder et al., 2001, "Adjuvanticity of α_2 -macroglobulin, an independent ligand for the heat shock protein receptor CD91," *J. Immunology* 166:4968-4972. Each of these references has already been disclosed in an Information Disclosure Statement filed in the subject application. Specifically, these references were disclosed in Information Disclosure Statements that were filed on September 25, 2001 and on July 30, 2003, respectively. A copy of the May 30, 2005 search report is attached hereto as **Exhibit A**.

Each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Supplemental Information Disclosure Statement. Pursuant to 37 C.F.R. §1.97(d), Applicants believe that a fee of **\$180.00** is due in connection with the filing of this Supplemental Information Disclosure Statement. Please charge this fee to Jones Day deposit account no. 50-3013.

Respectfully submitted,

Date: August 30, 2005


Adriane M. Antler 32,605
(Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017
Phone: (212) 901-9028



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-177-999	APPLICATION NO. 09/873,403
	APPLICANT Srivastava	
	FILING DATE June 4, 2001	GROUP 1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	EM	Binder et al., 2000, "CD91:A receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155

EXAMINER	DATE CONSIDERED
-----------------	------------------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.